Abliva AB Publishes 2023 Annual Report
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the English version of the Annual ...
Press releases
Notice of Annual General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, (“the Company or “Abliva”) are hereby convened to the Annual General Meeting, held at 1 p.m. on Thursday, 23 May 2024 at Me ...
Abliva publishes rights issue outcome
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva”) or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company on 22 February 202 ...
Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares
The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has, in connection with the preferential rights issue announced on 22 February 2024, prepared a prospectus (the ...
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today 26 March 2024 held an Extraordinary General Meeting. A summary of the resolutions follows. The resolutions were passed unanimou ...
Abliva AB Year-End Report January – December 2023
40 Patients Enrolled in Wave 1 of the FALCON Study | Fast Track Designation for KL1333 | Orphan Drug Designation for NV354 in both US and Europe
Notice of Extraordinary General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, (the “Company”), are hereby convened to the Extraordinary General Meeting (the “EGM”) to be held at 3 p.m. on Tuesday 26 Ma ...
The Board of Directors of Abliva resolves on a fully guaranteed rights issue of SEK 46 million and a directed issue of convertible bonds of SEK 42 million to prepare for the final stage of the FALCON study
The Board of Directors of Abliva AB (publ) (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) has today resolved on a capital raise totalling approximately SEK 88 million (the “Transaction”). The Tr ...
Abliva Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study
Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the goal of enrolling 40 patients ...
Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354
Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the European Commission has gr ...
Abliva AB Interim Report January – September 2023
KL1333 Received FDA Fast Track Designation | The FALCON Study Reached an Important Milestone
Abliva and Owl Therapeutics enter into licensing and collaboration agreement for NeuroSTAT® in Traumatic Brain Injury
Abliva AB (‘Abliva’ or the ‘Company’) and US-based Owl Therapeutics today announced the signing of a licensing and collaboration agreement for Abliva’s NeuroSTAT® for the treatment of moderate to seve ...